ABIOMED Stock News

Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022.

With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. The post 7 Medical Device Stocks to Buy as Covid-19 Fears Fade

The "Mad Money" host spoke with Abiomed CEO Mike Minogue on Monday's episode of the show.

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

They have a whole lot going right, and little in the way of obstacles.

Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.

Riding The Stock Waves: Update On The Medical Devices Sector

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Abiomed, Inc. , a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at… | February 8, 2022

Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript

Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.

Abiomed press release (ABMD): Q3 Non-GAAP EPS of $1.13 beats by $0.16.Revenue of $261.18M (+12.7% Y/Y) beats by $9.71M.The company is increasing the lower end of its fiscal year

Abiomed (ABMD) delivered earnings and revenue surprises of 15.31% and 3.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?